<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "4: Royalties ", fill: "#a52a2a"},
{source: "4: Royalties ", target: "4: currently constitute", fill: "#a52a2a"},
{source: "4: currently constitute", target: "4: significant", fill: "#a52a2a"},
{source: "4: Royalties ", target: "5: December ", fill: "#fba0e3"},
{source: "5: December ", target: "5: royalties from", fill: "#fba0e3"},
{source: "5: royalties from", target: "5: total revenues", fill: "#fba0e3"},
{source: "5: December ", target: "7: attributable", fill: "#0014a8"},
{source: "7: attributable", target: "7: generic fexofenadine", fill: "#0014a8"},
{source: "7: generic fexofenadine", target: "7: Barr Pharmaceuticals Inc", fill: "#0014a8"},
{source: "7: attributable", target: "9: September ", fill: "#0070ff"},
{source: "9: September ", target: "9: adverse impact on", fill: "#0070ff"},
{source: "9: adverse impact on", target: "9: Allegra ", fill: "#0070ff"},
{source: "9: September ", target: "10: Continued ", fill: "#967117"},
{source: "10: Continued ", target: "10: competition", fill: "#967117"},
{source: "10: competition", target: "10: additional generic competitors upon", fill: "#967117"},
{source: "10: additional generic competitors upon", target: "10: marketing generic", fill: "#967117"},
{source: "10: marketing generic", target: "10: fexofenadine", fill: "#967117"},
{source: "10: fexofenadine", target: "10: generic version", fill: "#967117"},
{source: "10: generic version", target: "10: AllegraD ", fill: "#967117"},
{source: "10: AllegraD ", target: "10: generic competitor may further adversely affect", fill: "#967117"},
{source: "10: Continued ", target: "11: of Allegra ", fill: "#ffdab9"},
{source: "11: of Allegra ", target: "11: decreases due", fill: "#ffdab9"},
{source: "11: decreases due", target: "11: revenues from", fill: "#ffdab9"},
{source: "11: revenues from", target: "11: agreement with", fill: "#ffdab9"},
{source: "11: agreement with", target: "11: SanofiAventis ", fill: "#ffdab9"},
{source: "11: SanofiAventis ", target: "11: will also decrease", fill: "#ffdab9"},
{source: "11: of Allegra ", target: "14: recurring royalties", fill: "#c72c48"},
{source: "14: recurring royalties", target: "14: AllegraTelfast ", fill: "#c72c48"},
{source: "14: AllegraTelfast ", target: "14: historically provided", fill: "#c72c48"},
{source: "14: historically provided", target: "14: revenues earnings", fill: "#c72c48"},
{source: "14: revenues earnings", target: "14: cash flows", fill: "#c72c48"},
{source: "14: recurring royalties", target: "17: September ", fill: "#1560bd"},
{source: "17: September ", target: "17: adverse impact on", fill: "#1560bd"},
{source: "17: adverse impact on", target: "17: fourth quarter", fill: "#1560bd"},
{source: "17: fourth quarter", target: "17: royalty revenues", fill: "#1560bd"},
{source: "17: September ", target: "22: Litigation ", fill: "#f0f8ff"},
{source: "22: Litigation ", target: "22: litigation", fill: "#f0f8ff"},
{source: "22: litigation", target: "22: timeconsuming", fill: "#f0f8ff"},
{source: "22: timeconsuming", target: "22: inherently uncertain", fill: "#f0f8ff"},
{source: "22: Litigation ", target: "24: or SanofiAventis ", fill: "#ffdead"},
{source: "24: or SanofiAventis ", target: "24: SanofiAventis ", fill: "#ffdead"},
{source: "24: SanofiAventis ", target: "24: exclusivity", fill: "#ffdead"},
{source: "24: exclusivity", target: "24: covered by", fill: "#ffdead"},
{source: "24: or SanofiAventis ", target: "START_HERE", fill: "#ffdead"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Economic</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Royalty_Exchange">Royalty Exchange</a></td>
      <td>Royalty Exchange is an American company that operates an online platform for buying and selling royalty assets of any type, mostly music, where royalty owners can sell their future payments to investors as alternative assets.  The company hosts a centralized marketplace and online auction platform that connects a community of over 22,500+ investors with owners of royalty-based assets.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_10">December 10</a></td>
      <td>December 10 is the 344th day of the year (345th in leap years) in the Gregorian calendar;  21 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n1317 – The "Nyköping Banquet": King Birger of Sweden treacherously seizes his two brothers Valdemar, Duke of Finland and Eric, Duke of Södermanland, who were subsequently starved to death in the dungeon of Nyköping Castle.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_18">December 18</a></td>
      <td>December 11 is the 345th day of the year (346th in leap years) in the Gregorian calendar;  20 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n220 – Emperor Xian of Han is forced to abdicate the throne by Cao Cao's son Cao Pi, ending the Han dynasty.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_31">December 31</a></td>
      <td>December 3 is the 337th day of the year (338th in leap years) in the Gregorian calendar;  28 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n915 – Pope John X crowns Berengar I of Italy as Holy Roman Emperor (probable date).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Khara_(studio)">Khara (studio)</a></td>
      <td>Khara, Inc. (株式会社カラー, Kabushiki-gaisha Karā, stylized as khara, Inc.) is a Japanese animation studio, located in Suginami, Tokyo, best known for its work on the Rebuild of Evangelion film tetralogy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Keith_Ape">Keith Ape</a></td>
      <td>Dongheon Lee (이동헌; born December 25, 1993), known professionally as Keith Ape (Korean: 키스 에이프) and previously known as Kid Ash, is a South Korean rapper from Seoul. He is a member of a crew called 'The Cohort'.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Terfenadine">Terfenadine</a></td>
      <td>Terfenadine is an antihistamine formerly used for the treatment of allergic conditions. It was brought to market by Hoechst Marion Roussel (now Sanofi-Aventis) and was marketed under various brand names, including Seldane in the United States, Triludan in the United Kingdom, and Teldane in Australia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Antihistamine">Antihistamine</a></td>
      <td>Antihistamines are drugs which treat allergic rhinitis, common cold, influenza, and other allergies.  Typically, people take antihistamines as an inexpensive, generic (not patented) drug that can be bought without a prescription and provides relief from nasal congestion, sneezing, or hives caused by pollen, dust mites, or animal allergy with few side effects.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Mirtazapine">Mirtazapine</a></td>
      <td>Mirtazapine, sold under the brand name Remeron among others, is an atypical antidepressant, and as such is used primarily to treat depression. Its effects may take up to four weeks, but can also manifest as early as one to two weeks.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Teva_Pharmaceuticals">Teva Pharmaceuticals</a></td>
      <td>Teva Pharmaceutical Industries Ltd. (also known as Teva Pharmaceuticals) is an Israeli multinational pharmaceutical company with headquarters in Petah Tikva, Israel.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Protriptyline">Protriptyline</a></td>
      <td>Protriptyline, sold under the brand name Vivactil among others, is a tricyclic antidepressant (TCA), specifically a secondary amine, indicated for the treatment of depression and attention-deficit hyperactivity disorder (ADHD). Uniquely among most of the TCAs, protriptyline tends to be energizing instead of sedating, and is sometimes used for narcolepsy to achieve a wakefulness-promoting effect.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Wyeth">Wyeth</a></td>
      <td>Wyeth, LLC was an American pharmaceutical company. The company was founded in Philadelphia, Pennsylvania, in 1860 as John Wyeth and Brother.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/September_10">September 10</a></td>
      <td>September 1 is the 244th day of the year (245th in leap years) in the Gregorian calendar;  121 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n1145 – The main altar of Lund Cathedral, at the time seat of the archiepiscopal see of all the Nordic countries, is consecrated.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/September_30">September 30</a></td>
      <td>September 3 is the 246th day of the year (247th in leap years) in the Gregorian calendar;  119 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n36 BC – In the Battle of Naulochus, Marcus Vipsanius Agrippa, admiral of Octavian, defeats Sextus Pompey, son of Pompey, thus ending Pompeian resistance to the Second Triumvirate.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Adverse_effect">Adverse effect</a></td>
      <td>An adverse effect is an undesired harmful effect resulting from a medication or other intervention, such as surgery. An adverse effect may be termed a "side effect", when judged to be secondary to a main or therapeutic effect.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Allegra_McEvedy">Allegra McEvedy</a></td>
      <td>Allegra Sarah Bazzett McEvedy MBE (born November 1970) is an English chef, broadcaster and writer.\n\n\n== Early life ==\nMcEvedy was born and raised in Hammersmith.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_generic_and_genericized_trademarks">List of generic and genericized trademarks</a></td>
      <td>The following three lists of generic and genericized trademarks are:\n\nmarks which were originally legally protected trademarks, but have been genericized and have lost their legal status due to becoming generic terms,\nmarks which have been abandoned and are now generic terms\nmarks which are still legally protected as trademarks, at least in some jurisdictions\n\n\n== List of former trademarks that have been genericized ==\nThe following partial list contains marks which were originally legally protected trademarks, but which have subsequently lost legal protection as trademarks by becoming the common name of the relevant product or service, as used both by the consuming public and commercial competitors. These marks were determined in court to have become generic.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Paul_Hudson_(businessman)">Paul Hudson (businessman)</a></td>
      <td>Paul Hudson (born 14 October 1967) is a British businessman, and the chief executive (CEO) of Sanofi, the world's fifth largest pharmaceutical company by prescription drug sales.\n\n\n== Early life ==\nHudson earned a degree in economics from Manchester Metropolitan University, and a diploma in marketing from the Chartered Institute of Marketing.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Valproate">Valproate</a></td>
      <td>Valproate (VPA) and its valproic acid, sodium valproate, and valproate semisodium forms are medications primarily used to treat epilepsy and bipolar disorder and prevent migraine headaches. They are useful for the prevention of seizures in those with absence seizures, partial seizures, and generalized seizures.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_seasonal_influenza_vaccines">List of seasonal influenza vaccines</a></td>
      <td>Seasonal influenza vaccine brands include Fluzone/Fluzone Quadrivalent and Vaxigrip/VaxigripTetra, Influvac and Optaflu.\n\n\n== AstraZeneca ==\nFluenz, FluMist and their quadrivalent formulations are nasal attenuated vaccines by AstraZeneca.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Irbesartan">Irbesartan</a></td>
      <td>Irbesartan, sold under the brand name Avapro among others, is a medication used to treat high blood pressure, heart failure, and diabetic kidney disease. It is a reasonable initial treatment for high blood pressure.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Discounted_cash_flow">Discounted cash flow</a></td>
      <td>In finance, discounted cash flow (DCF) analysis is a method of valuing a security, project, company, or asset using the concepts of the time value of money. \nDiscounted cash flow analysis is widely used in investment finance, real estate development, corporate financial management and patent valuation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Free_cash_flow">Free cash flow</a></td>
      <td>In corporate finance, free cash flow (FCF) or free cash flow to firm (FCFF) is the amount by which a business's operating cash flow exceeds its working capital needs and expenditures on fixed assets (known as capital expenditures). It is that portion of cash flow that can be extracted from a company and distributed to creditors and securities holders  without causing issues in its operations.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Free_cash_flow_to_equity">Free cash flow to equity</a></td>
      <td>In corporate finance, free cash flow to equity (FCFE) is a metric of how much cash can be distributed to the equity shareholders of the company as dividends or stock buybacks—after all expenses, reinvestments, and debt repayments are taken care of. It is also referred to as the levered free cash flow or the flow to equity (FTE).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Keystone_Pipeline">Keystone Pipeline</a></td>
      <td>The Keystone Pipeline System is an oil pipeline system in Canada and the United States, commissioned in 2010 and owned by TC Energy and as of 31 March 2020 the Government of Alberta. It runs from the Western Canadian Sedimentary Basin in Alberta to refineries in Illinois and Texas, and also to oil tank farms and an oil pipeline distribution center in Cushing, Oklahoma.TransCanada Keystone Pipeline GP Ltd, abbreviated here as Keystone, operates four phases of the project.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Lawsuit">Lawsuit</a></td>
      <td>A lawsuit is a proceeding by a party or parties against another in the civil court of law. The archaic term "suit in law" is found in only a small number of laws still in effect today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Settlement_(litigation)">Settlement (litigation)</a></td>
      <td>In law, a settlement is a resolution between disputing parties about a legal case, reached either before or after court action begins. A collective settlement is a settlement of multiple similar legal cases.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Vexatious_litigation">Vexatious litigation</a></td>
      <td>Vexatious litigation is legal action which is brought  solely to harass or subdue an adversary. It may take the form of a primary frivolous lawsuit or may be the repetitive, burdensome, and unwarranted filing of meritless motions in a matter which is otherwise a meritorious cause of action.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Multidistrict_litigation">Multidistrict litigation</a></td>
      <td>In United States law, multidistrict litigation (MDL) refers to a special federal legal procedure designed to speed the process of handling complex cases, such as air disaster litigation or complex product liability suits.\n\n\n== Description ==\nMDL cases occur when "civil actions involving one or more common questions of fact are pending in different districts." In order to efficiently process cases that could involve hundreds (or thousands) of plaintiffs in dozens of different federal courts that all share common issues, the Judicial Panel on Multidistrict Litigation (JPML) decides whether cases should be consolidated under MDL, and if so, where the cases should be transferred.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Strategic_litigation">Strategic litigation</a></td>
      <td>Strategic litigation, also known as impact litigation, is the practice of bringing lawsuits intended to effect societal change. Impact litigation cases may be class action lawsuits or individual claims with broader significance, and may rely on statutory law arguments or on constitutional claims.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Parallel_litigation">Parallel litigation</a></td>
      <td>Parallel litigation is a scenario in which different courts are hearing the same claim(s).  In the United States, parallel litigation (and the "race to judgement" that results)is a consequence of its system of "dual sovereignty, in which both state and federal courts have personal jurisdiction over the parties.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Exclusive_or">Exclusive or</a></td>
      <td>Exclusive or or exclusive disjunction is a logical operation that is true if and only if its arguments differ (one is true, the other is false).It is symbolized by the prefix operator J and by the infix operators XOR ( or ), EOR, EXOR, ⊻, ⩒, ⩛, ⊕, \n  \n    \n      \n        ↮\n      \n    \n    {\displaystyle \nleftrightarrow }\n  , and ≢. The negation of XOR is the logical biconditional, which yields true if and only if the two inputs are the same.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Exclusive_jurisdiction">Exclusive jurisdiction</a></td>
      <td>Exclusive jurisdiction exists in civil procedure if one court has the power to adjudicate a case to the exclusion of all other courts. The opposite situation is concurrent jurisdiction (or non-exclusive jurisdiction) in which more than one court may take jurisdiction over the case.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>ALBANY MOLECULAR RESEARCH INC      ITEM 1A        RISK FACTORS       The <font color="blue">following factors should</font> be considered <font color="blue">carefully</font> in addition to the     other information in this Form 10-K Except as mentioned under “Quantitative     and Qualitative Disclosure About Market Risk” and except for the historical     information contained herein, the discussion contained in this Form 10-K     contains “forward-looking statements,” within the meaning of Section 27A of     the <font color="blue">Securities Act and Section </font>21E of the Exchange Act, that <font color="blue">involve risks</font>     and <font color="blue">uncertainties</font></td>
    </tr>
    <tr>
      <td>Our actual results could differ materially from those     discussed  in  this  Form 10-K  <font color="blue">Important </font>factors that could cause or     contribute to <font color="blue">such differences</font> include those discussed below, as well as     those <font color="blue">discussed elsewhere herein</font></td>
    </tr>
    <tr>
      <td>The royalties we earn on Allegra <font color="blue">may continue</font> to decrease</td>
    </tr>
    <tr>
      <td><font color="blue">Royalties </font>from sales <font color="blue">of Allegra </font><font color="blue">currently constitute</font> a <font color="blue">significant</font> portion     of  our  total  revenues  and  operating income</td>
    </tr>
    <tr>
      <td>During the year ended     <font color="blue">December </font>31, 2005, our <font color="blue">royalties from</font> Allegra were dlra46dtta9 million, which     represented approximately 26prca of our <font color="blue">total revenues</font></td>
    </tr>
    <tr>
      <td>For the year ended     <font color="blue">December </font>31, 2004, our <font color="blue">royalties from</font> Allegra were dlra48dtta0 million, which     represented  approximately 28prca of our <font color="blue">total revenues</font></td>
    </tr>
    <tr>
      <td>The decrease is     primarily  <font color="blue">attributable</font>  to the at-risk launch of <font color="blue">generic <font color="blue">fexofenadine</font></font>     announced by Barr Pharmaceuticals, Inc</td>
    </tr>
    <tr>
      <td>on <font color="blue">September </font>6, 2005, which had a material <font color="blue">adverse <font color="blue">impact on</font></font> US sales     of  <font color="blue">Allegra  </font>in  the <font color="blue">fourth quarter</font> of 2005</td>
    </tr>
    <tr>
      <td><font color="blue">Continued </font>generic <font color="blue">Allegra  </font>   <font color="blue">competition</font>, including the entrance of <font color="blue">additional generic competitors upon</font>     the expiration of Barr’s 180-day <font color="blue">exclusivity</font> period for <font color="blue">marketing generic</font>     <font color="blue">fexofenadine</font> or an at-risk launch of a <font color="blue">generic version</font> of Allegra-D by a     generic competitor, may further adversely affect US sales of Allegra</td>
    </tr>
    <tr>
      <td>If     the  dollar  amount  <font color="blue">of Allegra </font>sales subject to our <font color="blue">license agreement</font>     decreases, due to these or any other factors, our <font color="blue">revenues from</font> our license     <font color="blue">agreement with</font> Sanofi-Aventis <font color="blue">will also decrease</font></td>
    </tr>
    <tr>
      <td>Because we have very few     <font color="blue">costs associated with</font> the Allegra license, a decrease in <font color="blue">revenues from</font> our     <font color="blue">license agreement</font> for Allegra would have a material adverse effect on our     revenue,  operating  income,  and  <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>For example, a     dlra5dtta0 million decrease in our Allegra <font color="blue">royalty revenue would decrease</font> our     operating income by dlra4dtta5 million</td>
    </tr>
    <tr>
      <td>The <font color="blue">recurring royalties</font> we receive on the sales of Allegra/Telfast have     <font color="blue">historically provided</font> a material portion of our revenues, earnings, and     operating <font color="blue">cash flows</font></td>
    </tr>
    <tr>
      <td>The at-risk launch of <font color="blue">generic <font color="blue">fexofenadine</font></font> announced     by Barr Pharmaceuticals, Inc</td>
    </tr>
    <tr>
      <td>and <font color="blue">Teva Pharmaceuticals Industries Ltd</font></td>
    </tr>
    <tr>
      <td>on     <font color="blue">September </font>6, 2005 had a material <font color="blue">adverse <font color="blue">impact on</font></font> US sales <font color="blue">of Allegra </font>in     the <font color="blue">fourth quarter</font> of 2005, resulting in a 49prca year-over-year decrease in     our <font color="blue">royalty revenues</font> for the <font color="blue">fourth quarter</font></td>
    </tr>
    <tr>
      <td>We currently expect that the     at-risk launch of <font color="blue">generic <font color="blue">fexofenadine</font></font> will have a similar <font color="blue">impact on</font> our     <font color="blue">royalty revenues</font> in <font color="blue">future periods</font></td>
    </tr>
    <tr>
      <td>We expect to experience a decrease in     revenues,  earnings,  and operating <font color="blue">cash flows</font> in the short term as we     continue to develop our business in an effort to supplement the revenues,     earnings and operating <font color="blue">cash flows</font> that have <font color="blue">historically been provided by</font>     Allegra/Telfast royalties</td>
    </tr>
    <tr>
      <td>We have <font color="blue">been issued several patents on</font> a pure form of, and a <font color="blue">manufacturing</font>     process for, <font color="blue">fexofenadine</font> HCl</td>
    </tr>
    <tr>
      <td>The <font color="blue">patent positions</font> of <font color="blue">pharmaceutical</font>,     medical and <font color="blue">biotechnology firms</font> can be uncertain and can <font color="blue">involve complex</font>     legal and factual questions</td>
    </tr>
    <tr>
      <td>Litigation, in particular patent <font color="blue">litigation</font>,     can be complex and time-consuming and the outcome is <font color="blue">inherently uncertain</font></td>
    </tr>
    <tr>
      <td>We  <font color="blue">cannot assure</font> our <font color="blue">stockholders</font> that Sanofi-Aventis <font color="blue">will ultimately</font>     succeed  in  its current or any future <font color="blue">litigation</font> against generic drug     <font color="blue">manufacturers</font>       16     ______________________________________________________________________       <font color="blue">involving patents <font color="blue">with respect</font></font> to Allegra</td>
    </tr>
    <tr>
      <td>In the event that one or more of     the patents owned by us or Sanofi-Aventis are ultimately determined to be     invalid or unenforceable, Sanofi-Aventis and we would lose <font color="blue">exclusivity</font> with     respect to the claims <font color="blue">covered by</font> those patents</td>
    </tr>
    <tr>
      <td>Any such loss of <font color="blue">exclusivity</font>     or  the  introduction of <font color="blue">generic forms</font> of <font color="blue">fexofenadine</font> HCl may cause a     reduction in Allegra sales</td>
    </tr>
    <tr>
      <td>In addition, under our <font color="blue">current arrangements with</font>     Sanofi-Aventis, Sanofi-Aventis, with consultation from us, has the right to     lead  <font color="blue">with respect</font> to preparing and executing a strategy to defend and     <font color="blue">enforce certain</font> of the patents relating to Allegra, and is executing that     role in the current <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>As a result, we may not be able to control     the conduct of such <font color="blue">litigation</font> and the <font color="blue">strategic decisions</font> that are made</td>
    </tr>
  </tbody>
</table>